Literature DB >> 19270292

Tropism of dengue virus in mice and humans defined by viral nonstructural protein 3-specific immunostaining.

Scott J Balsitis1, Josefina Coloma, Glenda Castro, Aracely Alava, Diana Flores, James H McKerrow, P Robert Beatty, Eva Harris.   

Abstract

Previous attempts to define dengue virus (DENV) tropism in human autopsy tissues have detected DENV antigens that are abundant in circulation during severe dengue, and thus may be present in uninfected cells. To better define DENV tropism, we performed immunostaining for the DENV2 nonstructural protein 3 (NS3) in humans and in a mouse model of DENV infection. In mice, NS3 was detected in phagocytes of the spleen and lymph node, hepatocytes in liver, and myeloid cells in bone marrow. In human autopsy tissues, NS3 was present in phagocytes in lymph node and spleen, alveolar macrophages in lung, and perivascular cells in brain. This protein was also found in hepatocytes in liver and endothelial cells in spleen, although NS3 was not present in endothelium in any other tissue. Thus, NS3-specific immunostaining supports roles for infected phagocytes, hepatocytes, and, to a limited degree, endothelial cells in the pathogenesis of severe dengue.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19270292

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  113 in total

1.  A lethal murine infection model for dengue virus 3 in AG129 mice deficient in type I and II interferon receptors leads to systemic disease.

Authors:  Vanessa V Sarathy; Mellodee White; Li Li; Summer R Gorder; Richard B Pyles; Gerald A Campbell; Gregg N Milligan; Nigel Bourne; Alan D T Barrett
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

2.  Complex phenotypes in mosquitoes and mice associated with neutralization escape of a Dengue virus type 1 monoclonal antibody.

Authors:  Bimmi Shrestha; S Kyle Austin; Kimberly A Dowd; Abhishek N Prasad; Soonjeon Youn; Theodore C Pierson; Daved H Fremont; Gregory D Ebel; Michael S Diamond
Journal:  Virology       Date:  2012-03-09       Impact factor: 3.616

3.  Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells.

Authors:  Simona Zompi; Brian H Santich; P Robert Beatty; Eva Harris
Journal:  J Immunol       Date:  2011-11-30       Impact factor: 5.422

Review 4.  Immune-mediated cytokine storm and its role in severe dengue.

Authors:  Anon Srikiatkhachorn; Anuja Mathew; Alan L Rothman
Journal:  Semin Immunopathol       Date:  2017-04-11       Impact factor: 9.623

5.  Mutagenesis of the DI/DIII linker in dengue virus envelope protein impairs viral particle assembly.

Authors:  Melissanne de Wispelaere; Priscilla L Yang
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

Review 6.  How innate immune mechanisms contribute to antibody-enhanced viral infections.

Authors:  Sukathida Ubol; Scott B Halstead
Journal:  Clin Vaccine Immunol       Date:  2010-09-28

7.  Quantitative proteomic analysis of host-virus interactions reveals a role for Golgi brefeldin A resistance factor 1 (GBF1) in dengue infection.

Authors:  Lindsay N Carpp; Richard S Rogers; Robert L Moritz; John D Aitchison
Journal:  Mol Cell Proteomics       Date:  2014-05-22       Impact factor: 5.911

Review 8.  Plasma leakage in dengue haemorrhagic fever.

Authors:  Anon Srikiatkhachorn
Journal:  Thromb Haemost       Date:  2009-12       Impact factor: 5.249

9.  Dengue reporter viruses reveal viral dynamics in interferon receptor-deficient mice and sensitivity to interferon effectors in vitro.

Authors:  John W Schoggins; Marcus Dorner; Michael Feulner; Naoko Imanaka; Mary Y Murphy; Alexander Ploss; Charles M Rice
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-20       Impact factor: 11.205

10.  The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase.

Authors:  Melissanne de Wispelaere; Amy J LaCroix; Priscilla L Yang
Journal:  J Virol       Date:  2013-04-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.